Glimepiride - Revision history

Fire: Marked this version for translation

2024-03-13T13:53:44Z

Marked this version for translation

← Older revision		Revision as of 22:53, 13 March 2024
Line 1:		Line 1:
	<languages />		<languages />
	<translate>		<translate>
			<!--T:1-->
	{{Short description\|Medication}}		{{Short description\|Medication}}
	{{drugbox		{{drugbox
Line 9:		Line 10:
	\| width = 300		\| width = 300

			<!--T:2-->
	<!-- Clinical data -->		<!-- Clinical data -->
	\| tradename = Amaryl, others		\| tradename = Amaryl, others
Line 20:		Line 22:
	\| ATC_supplemental =		\| ATC_supplemental =

			<!--T:3-->
	\| legal_AU = S4		\| legal_AU = S4
	\| legal_US = Rx-only		\| legal_US = Rx-only
	\| legal_status = Rx only		\| legal_status = Rx only

			<!--T:4-->
	<!--Pharmacokinetic data-->		<!--Pharmacokinetic data-->
	\| bioavailability = 100%		\| bioavailability = 100%
Line 33:		Line 37:
	\| excretion = Urine (~60%), feces (~40%)		\| excretion = Urine (~60%), feces (~40%)

			<!--T:5-->
	<!--Identifiers-->		<!--Identifiers-->
	\| CAS_number_Ref = {{cascite\|correct\|??}}		\| CAS_number_Ref = {{cascite\|correct\|??}}
Line 51:		Line 56:
	\| ChEMBL = 1481		\| ChEMBL = 1481

			<!--T:6-->
	<!-- Chemical data -->		<!-- Chemical data -->
	\| IUPAC_name = 3-Ethyl-4-methyl-''N''-[2-(4-<nowiki/>{[(''trans''-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1''H''-pyrrole-1-carboxamide		\| IUPAC_name = 3-Ethyl-4-methyl-''N''-[2-(4-<nowiki/>{[(''trans''-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1''H''-pyrrole-1-carboxamide
Line 68:		Line 74:
	'''Glimepiride''' is an [[antidiabetic medication]] within the [[sulfonylurea]] class, primarily prescribed for the management of [[type 2 diabetes]]. It is regarded as a second-line option compared to [[metformin]], due to metformin's well-established safety and efficacy. Use of glimepiride is recommended in conjunction with [[Lifestyle modification\|lifestyle modifications]] such as diet and exercise. It is taken by mouth, reaching a peak effect within three hours and lasting for about a day.		'''Glimepiride''' is an [[antidiabetic medication]] within the [[sulfonylurea]] class, primarily prescribed for the management of [[type 2 diabetes]]. It is regarded as a second-line option compared to [[metformin]], due to metformin's well-established safety and efficacy. Use of glimepiride is recommended in conjunction with [[Lifestyle modification\|lifestyle modifications]] such as diet and exercise. It is taken by mouth, reaching a peak effect within three hours and lasting for about a day.

			<!--T:7-->
	<!-- Side effects and mechanisms -->		<!-- Side effects and mechanisms -->
	Common side effects include headache, nausea, and dizziness. Serious side effects may include [[low blood sugar]]. Use during [[pregnancy]] and [[breastfeeding]] is not recommended. It is classified as a second-generation [[sulfonylurea]].		Common side effects include headache, nausea, and dizziness. Serious side effects may include [[low blood sugar]]. Use during [[pregnancy]] and [[breastfeeding]] is not recommended. It is classified as a second-generation [[sulfonylurea]].

			<!--T:8-->
	<!-- Society and culture -->		<!-- Society and culture -->
	Glimepiride was patented in 1979 and approved for medical use in 1995. It is available as a [[generic medication]]. In 2021, it was the 74th most commonly prescribed medication in the United States, with more than 8{{nbsp}}million prescriptions.		Glimepiride was patented in 1979 and approved for medical use in 1995. It is available as a [[generic medication]]. In 2021, it was the 74th most commonly prescribed medication in the United States, with more than 8{{nbsp}}million prescriptions.

	== Medical uses ==		== Medical uses == <!--T:9-->
	[[File:Glimepiride 2 MG Oral Tablet.jpg\|left\|thumb\|Two generic oral tablets of glimepiride, 2 mg each]]		[[File:Glimepiride 2 MG Oral Tablet.jpg\|left\|thumb\|Two generic oral tablets of glimepiride, 2 mg each]]
	Glimepiride is indicated to treat [[type 2 diabetes]]; its mode of action is to increase insulin secretion by the pancreas. However it requires adequate insulin synthesis as prerequisite to treat appropriately. It is not used for [[type 1 diabetes]] because in type 1 diabetes the pancreas is not able to produce insulin.		Glimepiride is indicated to treat [[type 2 diabetes]]; its mode of action is to increase insulin secretion by the pancreas. However it requires adequate insulin synthesis as prerequisite to treat appropriately. It is not used for [[type 1 diabetes]] because in type 1 diabetes the pancreas is not able to produce insulin.

	==Contraindications==		==Contraindications== <!--T:10-->
	Its use is contraindicated in patients with hypersensitivity to glimepiride or other sulfonylureas.		Its use is contraindicated in patients with hypersensitivity to glimepiride or other sulfonylureas.

	== Adverse effects ==		== Adverse effects == <!--T:11-->
	Side effects from taking glimepiride include [[gastrointestinal tract]] (GI) disturbances, occasional allergic reactions, and rarely blood production disorders including [[thrombocytopenia]], [[leukopenia]], and [[hemolytic anemia]]. In the initial weeks of treatment, the risk of hypoglycemia may be increased. Alcohol consumption and exposure to sunlight should be restricted because they can worsen side effects.		Side effects from taking glimepiride include [[gastrointestinal tract]] (GI) disturbances, occasional allergic reactions, and rarely blood production disorders including [[thrombocytopenia]], [[leukopenia]], and [[hemolytic anemia]]. In the initial weeks of treatment, the risk of hypoglycemia may be increased. Alcohol consumption and exposure to sunlight should be restricted because they can worsen side effects.

	== Interactions ==		== Interactions == <!--T:12-->
	[[Nonsteroidal anti-inflammatory drug]]s (such as [[salicylate]]s), [[Sulfonamide (medicine)\|sulfonamide]]s, [[chloramphenicol]], [[coumadin]] and [[probenecid]] may potentiate the [[hypoglycemic]] action of glimepiride. [[Thiazide]]s, other [[diuretic]]s, phothiazides, thyroid products, oral contraceptives, and [[phenytoin]] tend to produce [[hyperglycemia]].		[[Nonsteroidal anti-inflammatory drug]]s (such as [[salicylate]]s), [[Sulfonamide (medicine)\|sulfonamide]]s, [[chloramphenicol]], [[coumadin]] and [[probenecid]] may potentiate the [[hypoglycemic]] action of glimepiride. [[Thiazide]]s, other [[diuretic]]s, phothiazides, thyroid products, oral contraceptives, and [[phenytoin]] tend to produce [[hyperglycemia]].

	== Mechanism of action ==		== Mechanism of action == <!--T:13-->
	Like all [[sulfonylureas]], glimepiride acts as an insulin [[secretagogue]]. It lowers blood sugar by stimulating the release of insulin by pancreatic beta cells and by inducing increased activity of intracellular insulin receptors.		Like all [[sulfonylureas]], glimepiride acts as an insulin [[secretagogue]]. It lowers blood sugar by stimulating the release of insulin by pancreatic beta cells and by inducing increased activity of intracellular insulin receptors.

			<!--T:14-->
	Not all secondary sulfonylureas have the same risk of hypoglycemia. Glibenclamide (glyburide) is associated with an incidence of hypoglycemia of up to 20–30%, compared to as low as 2% to 4% with glimepiride. Glibenclamide also interferes with the normal homeostatic suppression of insulin secretion in reaction to hypoglycemia, whereas glimepiride does not. Also, glibenclamide diminishes glucagon secretion in reaction to hypoglycemia, whereas glimepiride does not.		Not all secondary sulfonylureas have the same risk of hypoglycemia. Glibenclamide (glyburide) is associated with an incidence of hypoglycemia of up to 20–30%, compared to as low as 2% to 4% with glimepiride. Glibenclamide also interferes with the normal homeostatic suppression of insulin secretion in reaction to hypoglycemia, whereas glimepiride does not. Also, glibenclamide diminishes glucagon secretion in reaction to hypoglycemia, whereas glimepiride does not.

	== Pharmacokinetics ==		== Pharmacokinetics == <!--T:15-->
	Gastrointestinal absorption is complete, with no interference from meals. Significant absorption can occur within one hour, and distribution is throughout the body, 99.5% bound to plasma protein. Metabolism is by oxidative biotransformation, it is [[Liver\|hepatic]] and complete. First, the medication is metabolized to M<sub>1</sub> metabolite by [[CYP2C9]]. M<sub>1</sub> possesses about {{frac\|1\|3}} of pharmacological activity of glimepiride, yet it is unknown if this results in clinically meaningful effect on blood glucose. M<sub>1</sub> is further metabolized to M<sub>2</sub> metabolite by cytosolic enzymes. M<sub>2</sub> is pharmacologically inactive. Excretion in the urine is about 65%, and the remainder is excreted in the feces.		Gastrointestinal absorption is complete, with no interference from meals. Significant absorption can occur within one hour, and distribution is throughout the body, 99.5% bound to plasma protein. Metabolism is by oxidative biotransformation, it is [[Liver\|hepatic]] and complete. First, the medication is metabolized to M<sub>1</sub> metabolite by [[CYP2C9]]. M<sub>1</sub> possesses about {{frac\|1\|3}} of pharmacological activity of glimepiride, yet it is unknown if this results in clinically meaningful effect on blood glucose. M<sub>1</sub> is further metabolized to M<sub>2</sub> metabolite by cytosolic enzymes. M<sub>2</sub> is pharmacologically inactive. Excretion in the urine is about 65%, and the remainder is excreted in the feces.


			<!--T:16-->
	{{Oral hypoglycemics}}		{{Oral hypoglycemics}}
	{{Prostanoidergics}}		{{Prostanoidergics}}
Line 101:		Line 111:
	{{Portal bar \| Medicine}}		{{Portal bar \| Medicine}}

			<!--T:17-->
	{{二次利用\|date= 4 February 2024}}		{{二次利用\|date= 4 February 2024}}
	[[Category:Potassium channel blockers]]		[[Category:Potassium channel blockers]]

Fire at 13:53, 13 March 2024

2024-03-13T13:53:31Z

← Older revision		Revision as of 22:53, 13 March 2024
Line 1:		Line 1:
			<languages />
			<translate>
	{{Short description\|Medication}}		{{Short description\|Medication}}
	{{drugbox		{{drugbox
Line 105:		Line 107:
	[[Category:Sanofi]]		[[Category:Sanofi]]
	[[Category:Wikipedia medicine articles ready to translate]]		[[Category:Wikipedia medicine articles ready to translate]]
			</translate>

Fire at 13:11, 13 March 2024

2024-03-13T13:11:07Z

← Older revision		Revision as of 22:11, 13 March 2024
Line 64:		Line 64:
	}}		}}
	<!-- Definition and medical uses -->		<!-- Definition and medical uses -->
	'''Glimepiride''' is an [[antidiabetic medication]] within the [[sulfonylurea]] class, primarily prescribed for the management of [[type 2 diabetes]]. It is regarded as a second-line option compared to [[metformin]], due to metformin's well-established safety and efficacy.~~<ref name=AHFS2019/>~~ Use of glimepiride is recommended in conjunction with [[Lifestyle modification\|lifestyle modifications]] such as diet and exercise. It is taken by mouth,~~<ref name=AHFS2019/>~~ reaching a peak effect within three hours and lasting for about a day.		'''Glimepiride''' is an [[antidiabetic medication]] within the [[sulfonylurea]] class, primarily prescribed for the management of [[type 2 diabetes]]. It is regarded as a second-line option compared to [[metformin]], due to metformin's well-established safety and efficacy. Use of glimepiride is recommended in conjunction with [[Lifestyle modification\|lifestyle modifications]] such as diet and exercise. It is taken by mouth, reaching a peak effect within three hours and lasting for about a day.

	<!-- Side effects and mechanisms -->		<!-- Side effects and mechanisms -->
Line 70:		Line 70:

	<!-- Society and culture -->		<!-- Society and culture -->
	Glimepiride was patented in 1979 and approved for medical use in 1995. It is available as a [[generic medication]].~~<ref name=BNF76/>~~ In 2021, it was the 74th most commonly prescribed medication in the United States, with more than 8{{nbsp}}million prescriptions.		Glimepiride was patented in 1979 and approved for medical use in 1995. It is available as a [[generic medication]]. In 2021, it was the 74th most commonly prescribed medication in the United States, with more than 8{{nbsp}}million prescriptions.

	== Medical uses ==		== Medical uses ==

Fire: Created page with "{{Short description|Medication}} {{drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 412761821 | image = Glimepiride.svg | width = 300 | tradename = Amaryl, others | Drugs.com = {{drugs.com|monograph|glimepiride}} | MedlinePlus = a696016 | DailyMedID = Glimepiride | pregnancy_AU = C | routes_of_administration = Oral administration|By mouth..."

2024-03-13T13:10:10Z

Created page with "{{Short description|Medication}} {{drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 412761821 | image = Glimepiride.svg | width = 300  | tradename = Amaryl, others | Drugs.com = {{drugs.com|monograph|glimepiride}} | MedlinePlus = a696016 | DailyMedID = Glimepiride | pregnancy_AU = C | routes_of_administration = Oral administration|By mouth..."

New page

{{Short description|Medication}}
{{drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 412761821
| image = Glimepiride.svg
| width = 300


| tradename = Amaryl, others
| Drugs.com = {{drugs.com|monograph|glimepiride}}
| MedlinePlus = a696016
| DailyMedID = Glimepiride
| pregnancy_AU = C
| routes_of_administration = [[Oral administration|By mouth]]
| ATC_prefix = A10
| ATC_suffix = BB12
| ATC_supplemental =

| legal_AU = S4
| legal_US = Rx-only
| legal_status = Rx only


| bioavailability = 100%
| protein_bound = >99.5%
| metabolism = Complete [[Liver]] (1st stage through [[CYP2C9]])
| onset = 2–3 hours
| elimination_half-life = 5–8 hours
| duration_of_action = 24 hours
| excretion = Urine (~60%), feces (~40%)


| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 93479-97-1
| PubChem = 3476
| IUPHAR_ligand = 6820
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB00222
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 16740595
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 6KY687524K
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00593
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 5383
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1481


| IUPAC_name = 3-Ethyl-4-methyl-''N''-[2-(4-<nowiki/>{[(''trans''-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1''H''-pyrrole-1-carboxamide
| C = 24
| H = 34
| N = 4
| O = 5
| S = 1
| smiles = O=C3C(/CC)=C(/C)CN3C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WIGIZIANZCJQQY-RUCARUNLSA-N
| melting_point = 207
}}

'''Glimepiride''' is an [[antidiabetic medication]] within the [[sulfonylurea]] class, primarily prescribed for the management of [[type 2 diabetes]]. It is regarded as a second-line option compared to [[metformin]], due to metformin's well-established safety and efficacy.<ref name=AHFS2019/> Use of glimepiride is recommended in conjunction with [[Lifestyle modification|lifestyle modifications]] such as diet and exercise. It is taken by mouth,<ref name=AHFS2019/> reaching a peak effect within three hours and lasting for about a day.


Common side effects include headache, nausea, and dizziness. Serious side effects may include [[low blood sugar]]. Use during [[pregnancy]] and [[breastfeeding]] is not recommended. It is classified as a second-generation [[sulfonylurea]].


Glimepiride was patented in 1979 and approved for medical use in 1995. It is available as a [[generic medication]].<ref name=BNF76/> In 2021, it was the 74th most commonly prescribed medication in the United States, with more than 8{{nbsp}}million prescriptions.

== Medical uses ==
[[File:Glimepiride 2 MG Oral Tablet.jpg|left|thumb|Two generic oral tablets of glimepiride, 2 mg each]]
Glimepiride is indicated to treat [[type 2 diabetes]]; its mode of action is to increase insulin secretion by the pancreas. However it requires adequate insulin synthesis as prerequisite to treat appropriately. It is not used for [[type 1 diabetes]] because in type 1 diabetes the pancreas is not able to produce insulin.

==Contraindications==
Its use is contraindicated in patients with hypersensitivity to glimepiride or other sulfonylureas.

== Adverse effects ==
Side effects from taking glimepiride include [[gastrointestinal tract]] (GI) disturbances, occasional allergic reactions, and rarely blood production disorders including [[thrombocytopenia]], [[leukopenia]], and [[hemolytic anemia]]. In the initial weeks of treatment, the risk of hypoglycemia may be increased. Alcohol consumption and exposure to sunlight should be restricted because they can worsen side effects.

== Interactions ==
[[Nonsteroidal anti-inflammatory drug]]s (such as [[salicylate]]s), [[Sulfonamide (medicine)|sulfonamide]]s, [[chloramphenicol]], [[coumadin]] and [[probenecid]] may potentiate the [[hypoglycemic]] action of glimepiride. [[Thiazide]]s, other [[diuretic]]s, phothiazides, thyroid products, oral contraceptives, and [[phenytoin]] tend to produce [[hyperglycemia]].

== Mechanism of action ==
Like all [[sulfonylureas]], glimepiride acts as an insulin [[secretagogue]]. It lowers blood sugar by stimulating the release of insulin by pancreatic beta cells and by inducing increased activity of intracellular insulin receptors.

Not all secondary sulfonylureas have the same risk of hypoglycemia. Glibenclamide (glyburide) is associated with an incidence of hypoglycemia of up to 20–30%, compared to as low as 2% to 4% with glimepiride. Glibenclamide also interferes with the normal homeostatic suppression of insulin secretion in reaction to hypoglycemia, whereas glimepiride does not. Also, glibenclamide diminishes glucagon secretion in reaction to hypoglycemia, whereas glimepiride does not.

== Pharmacokinetics ==
Gastrointestinal absorption is complete, with no interference from meals. Significant absorption can occur within one hour, and distribution is throughout the body, 99.5% bound to plasma protein. Metabolism is by oxidative biotransformation, it is [[Liver|hepatic]] and complete. First, the medication is metabolized to M1 metabolite by [[CYP2C9]]. M1 possesses about {{frac|1|3}} of pharmacological activity of glimepiride, yet it is unknown if this results in clinically meaningful effect on blood glucose. M1 is further metabolized to M2 metabolite by cytosolic enzymes. M2 is pharmacologically inactive. Excretion in the urine is about 65%, and the remainder is excreted in the feces.

{{Oral hypoglycemics}}
{{Prostanoidergics}}
{{Ion channel modulators}}
{{Portal bar | Medicine}}

{{二次利用|date= 4 February 2024}}
[[Category:Potassium channel blockers]]
[[Category:1-(Benzenesulfonyl)-3-cyclohexylureas]]
[[Category:Gamma-lactams]]
[[Category:Sanofi]]
[[Category:Wikipedia medicine articles ready to translate]]